Basics Altimmune, Inc. Altimmune Inc is a clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. IPO Date: May 22, 2017 Sector: Healthcare Industry: Biotech Market Cap: $356.56M Activated in VL: True Average Daily Range Avg Daily Range: $0.30 | 4.11% Avg Daily Range (30 D): $0.07 | 1.90% Avg Daily Range (90 D): $0.12 | 2.85% Institutional Daily Volume Avg Daily Volume: 1.84M Avg Daily Volume (30 D): 2.57M Avg Daily Volume (90 D): 4.28M Trade Size Avg Trade Size (Sh.): 159 Avg Trade Size (Sh.) (30 D): 202 Avg Trade Size (Sh.) (90 D): 200 Institutional Trades Total Inst.Trades: 1,466 Avg Inst. Trade: $1.72M Avg Inst. Trade (30 D): $2.36M Avg Inst. Trade (90 D): $1.57M Avg Inst. Trade Volume: .19M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.96M Avg Closing Trade (30 D): $1.37M Avg Closing Trade (90 D): $1.33M Avg Closing Volume: 224.53K     News Oct 6, 2025 @ 3:40 AM ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investig... Source: James (Josh) Wilson Oct 5, 2025 @ 4:00 PM ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman ... Source: Bronstein, Gewirtz & Grossman Llc Oct 4, 2025 @ 12:02 AM ALT FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING FI... Source: Rosen Law Firm Oct 2, 2025 @ 11:58 AM ALT Investors Have Opportunity to Lead Altimmune, ... Source: Prnewswire Oct 1, 2025 @ 4:00 PM ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman ... Source: Bronstein, Gewirtz & Grossman Llc Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.27 $-.26 Diluted EPS $-.27 $-.26 Revenue $ $ .01M $ .01M Gross Profit $ $ $ Net Income / Loss $ $ -22.15M $ -19.58M Operating Income / Loss $ $ -22.92M $ -21.82M Cost of Revenue $ $ $ Net Cash Flow $ $ 134M $ 12.18M PE Ratio     Splits Sep 14, 2018:   1:30 May 05, 2017:   1:10 May 04, 2017:   1:10 Jul 25, 2007:   1:50